"I referred this board to ARQL a week or so ago. Chart is uber-bullish :-)" It's not uncommon for biotechs to recover after getting pounded by a negative binary event. I traded DVAX after their AdComm and you saw the front end of the KERX debacle. ARQL caught a double whammy, first one pivotal lung cancer trial was suspended for safety and then their second trial was shut down early for efficacy. The current plan is to pursue refractory HCC overexpressing cMET. InterestinglyARQL's trial may overlap with a planned Comet trial in refractory HCC, likely to not include the cMET limitation. I realize your not looking to the long term and plan a short term trade, but I still see problems at ARQL. Their lead drug is faltering and they will need to raise money at some point in the not too distant future.